Patent Application
20090311339
The present invention relates to natural pharmaceutically active compounds, and can be used to obtain antiviral medications and to treat viral infections.
Known are pharmaceuticals that include complex of extractive substances from animal and vegetative tissues, which are used for treatment of viral infections by immunopotentiation and direct impact on virions or virus infected cells.
The method for producing proteins from CD4-positive T-lymphocytes and bone marrow cells, which proteins suppress development of human immunodeficiency virus, is known [U.S. Pat. No. 5,480,782] (1).
The external drug that includes extract of Ginkgo biloba and possesses antiviral and antibacterial activity, is known [DE pat. 4334600 A1] (2).
The patent WO 81/03124 [3] discloses polypeptide fraction extracted from Mytilus edulis mollusk, which fraction is active against various viruses, bacteria and protozoa.
Known are phytogenic antiviral drugs, which action mechanism is based on inactivation of free viral particles, blockage of their transport through cell membrane, or suppression of virus replication in host cell [Ershov F. I. Antiviral preparations, Moscow, Medicina, 1998] (4).
Known is the multi-component composition obtained from tissues of Calliphora vicina Robineau-Desvoidy (Diptera, Calliphoridae) insect and exhibiting an antiviral activity [U.S. Pat. No. 6,337,093] (5). From this composition, the peptide alloferon has been obtained, which possesses antiviral and antitumor activity [RU 2172322] (6). Antiviral activity of said composition and alloferon as its reactant is caused by immunopotentiating properties: ability to induce interferon synthesis and to enhance cytotoxic activity of natural killers [Chernysh et al. Antiviral and antitumor peptides from insects // PNAS, 2002, 99, p. 12628-12632] (7). At the same time, neither said composition nor alloferon provide direct protective influence upon cells subjected to viral infection.
Said composition and alloferon as its reactant is the only antiviral agent obtained from insects known at present. Under this attribute, they are the closest analogs of the present invention.
Natural pharmaceuticals mentioned above and natural analogs thereof extend the store of antiviral agents. However, pharmaceuticals known from the art do not cover existing needs, and in this connection, viral infections are still the most dangerous and intractable group of human and animal diseases.
So, the object of the present invention is in extending the store of antiviral pharmaceuticals.
While creating the present invention, it has been discovered that hemolymph of various insects comprises extractive substances, which increase, when being introduced into mammal cells, viral infection resistance of said cell culture. Further systematic study of pterygots (class Insecta, subclass Pterigota) allowed to disclose that analogous antiviral activity is present in several taxonomic ranks: species, genera, families and orders. As a result, a methodology for search of antiviral medications, which are included in insect tissues, has been elaborated. Basing upon said methodology, species and groups of higher rank, which are the most perspective as source of antiviral substances, have been determined.
Thus, the subject-matter of the present invention relates to the novel group of antiviral medications, direct action antiviral medications, obtained by extraction from insect tissues, particularly from representatives of orders of Odonata (dragonflies), Mantoptera (soothsayers), Hemiptera (hemipterans), Coleoptera (beetles), Diptera (two-winged flies), Mecoptera (scorpion flies) and Lepidoptera (scale-winged insects).
Medications of direct action, in the case, implicate individual substances or mixtures thereof, which increase resistance of organism cells towards viral infection by destruction of virus, blockage of replication thereof or by other way, which can run aside from immune system. Distinctive and generic feature of such medications is the increase of target cell resistance towards viral attack outside the organism (in vitro), e.g. when medication is introduced into cultural media with cells. Within the context of the present invention, the antonym for direct action medications are immunomodulators, which pharmaceutical activity is based upon stimulation of organism immune response. It is obvious that some insect metabolites can possess properties of antiviral medication with both direct and immunomodulating action mechanism. The latter fact should not prevent these materials to be included in claimed group of medications, provided that therapeutic efficacy of said substances is caused completely or partially by direct antiviral action.
It is also obvious that antiviral substances primarily obtained from insect tissues can be reproduced by means of chemical or biological synthesis, and are used in the same or modified form as medications. Basic structure can be modified in order to increase stability, bioavailability, and antiviral activity, and to decrease toxicity or other side effects of medication. Individual substances thus obtained or mixtures thereof can be used as a part of pharmaceutical compositions and in combination with other antiviral drugs.
Above-mentioned set of direct action antiviral substances obtained from insect tissues is proposed to be called entovirones (“ento-” from Greek “entomon”—insect, and “-viron” from Latin “virus”).
In order to study entovirones distribution within class of insects, hemolymph samples from 31 insect species were studied within one technique:
Presence of entovirones has been established in samples from 26 species, which relate to all of orders of insects under investigation (Table 1). Only 5 samples have displayed the negative result.
Investigated orders, as one can see from
Although entovirons are widespread throughout insects, their activity differs substantially when compared with representatives of various groups. Most active are entovirons of Odonata (dragonflies) order, particularly of dragonflies from Aeschnidae family like Aeschna grandis and Aeschna cyanea as well as from Libellulidae particularly Libellula quadrimaculata and Somatochlora metallica. Another group possessing high entovirons activity is a part of Lepidoptera order Noctuidae family represented by Diachrysia chrysitis and Mamestra persicaria species of the said family, as well as of Geometridae family (e.g. Operophtera brumata). Moreover, high entovirons activity is typical for several representatives of Coleoptera (Pseudophonus rufipes, Carabidae) and Diptera (Stratiomys singularior, Stratiomyidae) orders. Representatives of said species, families and orders are the most effective sources of entovirons.
Initial experimental biological material (insect larvae of certain order and development stage) were obtained from natural populations. After determining the species of each insect, they were kept in laboratory at ambient temperature and natural humidity. Immune system of insects was activated by puncturing cuticle with a needle wetted with a suspension of heat-killed (1 min in boiling water bath) Escherichia coli and Micrococcus luteus bacteria (109 cells of each type per 1 ml). Thus immunized larvae were incubated at ambient temperature for 24 hours. After that the surface of larvae was sterilized with 70% ethanol, next larvae were washed by sterilized distilled water and predried at filter paper. Hemolymph of larvae was collected through cuticle incision into ice-cooled test-tubes containing aprotinine and phenylthiourea in order to suppress proteolytic and phenoloxidase activity of hemolymph. Obtained samples were immediately frozen in liquid nitrogen and stored before use at −20° C.
Unfrozen hemolymph was centrifuged at 4000 g for 10 min and supernatant was acidified by trifluoroacetic acid until acid concentration reached 0.05% (v/v). Thus obtained sample was deposited on Sep-Pak column with C18 sorbent (Waters company) on the basis of 3 ml of hemolymph per 1 g of sorbent. The column was washed with 0.05% trifluoroacetic acid to remove hydrophilic components of hemolymph. After that adsorbed hydrophobic components were eluted by 50% acetonitrile in 0.05% trifluoroacetic acid. Thus obtained mixture of hydrophobic components was freeze-dried and used for further antiviral activity studies.
Antiviral activity was determined in vitro using common system for interferon antiviral activity determination (Chernysh et al. Antiviral and antitumor peptides from insects // PNAS, 2002, 99, p. 12628-12632). Human cell culture L41 was incubated in wells of 96-well culture plates until cell monolayer is formed on the bottom of each well. Then the substance under test was placed into wells. Simultaneously vesicular stomatitis virus (VSV, Indiana strain) in a dose equal to 100 CD50 (cytopathogenic dose causing death of 50% monolayer cells) was added into wells. Equivalent quantity of pure solvent was added to control wells. Cell culture infected by virus was incubated at 37° C. for 18 hours, then cells were visualized by 0.1% solution of a crystal-purple dye. Percentage of cells destroyed by the virus was estimated using measurements of optical density of extracted dye at the wavelength of 590 nm. Increase of survived monolayer cells percentage compared to controls indicated the activity of entovirons. Obtained results were rated as positive when certainty level for differences between experiment and control was less than 0.01 (P<0.01) according to Student's test.
Results of antiviral activity studies for hemolymph samples obtained from 31 insect species are presented in Table 1. Positively rated samples are marked as “”. There were 26 positive rated samples, or 84% of the full experimental set. As one can see from
Four sample groups relating to certain orders and families rise above investigated samples due to their high entoviron activity. The first group includes samples obtained from hemolymph of dragonflies (Odonata order), which are represented by Aeschnidae and Libellulidae families (Aeschna grandis and Libellula quadrimaculata, respectively). The second group includes samples obtained from Coleoptera order, which is represented by Carabidae family (e.g. Pseudophonus rufipes). The third group includes hemolymph samples from Lepidoptera, which is represented by Noctuidae family on an example of Diachrysia chrysitis and Mamestra persicaria noctuids as well as Geometridae family on an example of Operophtera brumata geometrid. And the last, fourth group includes samples obtained from Diptera order, represented by Stratiomyidae family on an example of Stratiomys singularior.
Listed orders, families and species are the most effective sources of entovirons.
Best variant of the invention embodiment is presented in the Example 1 describing a method of entovirons isolation, and Example 2 demonstrating antiviral activity of different representatives of the group of antiviral preparations. According to the data obtained, entoviron of an insect Libellula quadrimaculata demonstrates maximum antiviral activity.
Industrial applicability of the invention is confirmed by the results disclosed in the application and demonstrating that entoviron use allows to effectively prevent virus infected cells death, which is a goal of antiviral therapy. Because of that entovirons could be used for treatment of viral infections. Since industrial technologies of bioactive materials production are well developed for the time being, entovirons manufacturing by chemical or biological methods has no great difficulty.
Aeschna cyanea
Aeschna grandis
Libellula quadrimaculata
Somatochlora metallica
Iris polystictica
Aphrophora salicina
Pseudophonus rufipes
Acanthocinuss aedilis
Nicrophorus vespillo
Delia brassicae
Calliphora uralensis
Musca domestica
Epysyrphus balteatus
Stratiomys singularior
Gasterophilus veterinus
Lunatipula sublunata
Panorpa communis
Vespa crabro
Diprion pini
Athalia colibri
Mamestra persicaria
Diachrysia chrysitis
Operophtera brumata
Cossus cossus
Dendrolimus sibiricus
Lasiocampa trifoli
Axylia putris
Notodonta dromedarius
Sphinx ligustri
Ephestia kuhniella
Tortrix viridana
| Number | Date | Country | Kind |
|---|---|---|---|
| 2004100857 | Jan 2004 | RU | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/RU2004/000542 | 12/30/2004 | WO | 00 | 4/21/2009 |
